Katherine A Sitko
Overview
Explore the profile of Katherine A Sitko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boyle G, Sitko K, Galloway J, Haddox H, Bianchi A, Dixon A, et al.
Genetics
. 2024 Sep;
228(3).
PMID: 39319420
The cytochrome P450s enzyme family metabolizes ∼80% of small molecule drugs. Variants in cytochrome P450s can substantially alter drug metabolism, leading to improper dosing and severe adverse drug reactions. Due...
2.
Chakraborty S, Ahler E, Simon J, Fang L, Potter Z, Sitko K, et al.
Cell Chem Biol
. 2023 Sep;
31(2):207-220.e11.
PMID: 37683649
Kinase inhibitors are effective cancer therapies, but resistance often limits clinical efficacy. Despite the cataloging of numerous resistance mutations, our understanding of kinase inhibitor resistance is still incomplete. Here, we...
3.
Nguyen V, Ahler E, Sitko K, Stephany J, Maly D, Fowler D
Protein Sci
. 2023 May;
32(7):e4656.
PMID: 37167432
Hsp90 is a molecular chaperone involved in the refolding and activation of numerous protein substrates referred to as clients. While the molecular determinants of Hsp90 client specificity are poorly understood...
4.
Amorosi C, Chiasson M, McDonald M, Wong L, Sitko K, Boyle G, et al.
Am J Hum Genet
. 2021 Jul;
108(9):1735-1751.
PMID: 34314704
CYP2C9 encodes a cytochrome P450 enzyme responsible for metabolizing up to 15% of small molecule drugs, and CYP2C9 variants can alter the safety and efficacy of these therapeutics. In particular,...
5.
Chiasson M, Rollins N, Stephany J, Sitko K, Matreyek K, Verby M, et al.
Elife
. 2020 Sep;
9.
PMID: 32870157
Vitamin K epoxide reductase (VKOR) drives the vitamin K cycle, activating vitamin K-dependent blood clotting factors. VKOR is also the target of the widely used anticoagulant drug, warfarin. Despite VKOR's...
6.
Ahler E, Register A, Chakraborty S, Fang L, Dieter E, Sitko K, et al.
Mol Cell
. 2019 Apr;
74(2):393-408.e20.
PMID: 30956043
Multiple layers of regulation modulate the activity and localization of protein kinases. However, many details of kinase regulation remain incompletely understood. Here, we apply saturation mutagenesis and a chemical genetic...
7.
McDonald M, Ray S, Amorosi C, Sitko K, Kowalski J, Paco L, et al.
Drug Metab Dispos
. 2017 Oct;
45(12):1364-1371.
PMID: 29018033
CYP4Z1 is an "orphan" cytochrome P450 (P450) enzyme that has provoked interest because of its hypothesized role in breast cancer through formation of the signaling molecule 20-hydroxyeicosatetraenoic acid (20-HETE). We...
8.
Jung S, Smith J, von Haller P, Dilworth D, Sitko K, Miller L, et al.
Mol Cell Proteomics
. 2013 Jan;
12(5):1421-35.
PMID: 23349476
Cellular control of protein activities by modulation of their abundance or compartmentalization is not easily measured on a large scale. We developed and applied a method to globally interrogate these...